Continuation of therapeutic dose heparin for critically ill patients with COVID-19

Charlotte A. Bradbury, Patrick R. Lawler, Bryan J. McVerry, Ryan Zarychanski, on behalf of the REMAP-C. A. P. Investigators, Shailesh Bihari, Allen C. Cheng

Research output: Contribution to journalLetterpeer-review

3 Citations (Scopus)


Randomized trials demonstrated improved clinical outcomes when therapeutic-dose heparin is administered to non-critically ill patients hospitalized for coronavirus disease 2019 (COVID-19) and this is now recommended in practice guidelines. In contrast, clinical trials showed that therapeutic-dose heparin is not beneficial, and potentially harmful, when initiated in critically ill patients. Therefore, it is uncertain whether therapeutic-dose heparin should continue or be dose reduced when a patient transitions from non-critically ill to critically ill...
Original languageEnglish
Pages (from-to)873-875
Number of pages3
JournalIntensive Care Medicine
Issue number7
Publication statusPublished - Jul 2023


  • COVID-19
  • Heparin
  • Drug therapy
  • Patient outcomes


Dive into the research topics of 'Continuation of therapeutic dose heparin for critically ill patients with COVID-19'. Together they form a unique fingerprint.

Cite this